| Authors: |
Arance A; Department of Medical Oncology, Hospital Clínic Barcelona and Translational Genomics and Targeted Therapies in Solid Tumours Research Group (IDIBAPS), Barcelona, Spain. Electronic address: amarance@clinic.cat., Berciano-Guerrero MA; Department of Medical Oncology, Hospital Regional Universitario (HRU), Instituto de Investigaciones Biomédicas de Málaga-Plataforma BIONAND (IBIMA-BioNAND), Málaga, Spain., Guo J; Department of Melanoma and Renal Cancer, Beijing University Cancer Hospital, Beijing, China., Carlino MS; Melanoma Institute Australia, Westmead and Blacktown Hospitals, University of Sydney, Sydney, Australia., Ascierto PA; Department of Skin Cancers, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione G Pascale, Naples, Italy., Burotto M; Centro de Investigación Clínica Bradford Hill, Santiago, Chile., Mortier L; Department of Dermatology, Université Lille, CHRU Lille, INSERM U1189, Lille, France., Queirolo P; Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, European Institute of Oncology (IEO), IRCCS, Milan, Italy., Chiarion-Sileni V; Melanoma Oncology Unit, Istituto Oncologico Veneto, IOV-IRCCS, Padova, Italy., Schachter J; Oncology Division, Sheba Medical Center, Tel HaShomer Hospital, Ramat Gan, Israel., Zhang X; Department of Medical Oncology, Sun Yat-sen University Cancer Centre, Guangzhou, China., Martin-Liberal J; Instituto Català d'Oncologia (ICO)-Hospital Duran i Reynals, Barcelona, Spain., Del Vecchio M; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Okpara CE; Eisai Ltd., Hatfield, UK., Dutcus C; Eisai Inc., Nutley, NJ, USA., Zhang J; Merck & Co. Inc., Rahway, NJ, USA., Diede SJ; Merck & Co. Inc., Rahway, NJ, USA., Neff T; Merck & Co. Inc., Rahway, NJ, USA., Long GV; Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, Australia. |
